
Solid Biosciences (SLDB) Stock Forecast & Price Target
Solid Biosciences (SLDB) Analyst Ratings
Bulls say
Solid Biosciences is a promising investment opportunity due to continued progress in their gene therapy portfolio, particularly with their current lead candidate SGT-003 for the treatment of Duchenne muscular dystrophy, as well as potential treatments for other genetic diseases. The company has a strong cash position and positive interactions with the FDA, indicating a potential accelerated approval pathway for SGT-003. With a diverse and innovative platform and ongoing Phase 3 trials, Solid Biosciences remains a top pick for longer-term investors.
Bears say
Solid Biosciences is a life sciences company that operates in a single segment, developing treatments for neuromuscular and cardiac diseases through gene therapy and other means. However, the company has faced challenges, reporting a loss in the first quarter despite having a strong cash position and expecting to have enough funds through 2028. Additionally, the company's success in the market is dependent on its ability to execute commercially and navigate competition from other players in the field, making it a risky investment option.
This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Solid Biosciences (SLDB) Analyst Forecast & Price Prediction
Start investing in Solid Biosciences (SLDB)
Order type
Buy in
Order amount
Est. shares
0 shares